

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroTech Medical (Hangzhou) Co., Ltd.

微泰醫療器械（杭州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2235)

CONTINUING CONNECTED TRANSACTION REGARDING THE RAW MATERIAL PURCHASE FRAMEWORK AGREEMENT

On 21 August 2026 (after the trading hours), the Company entered into the Raw Material Purchase Framework Agreement (the “**Raw Material Purchase Framework Agreement**”) with Hangzhou Shukang Intelligent Manufacturing Technology Co., Ltd. (杭州數康智造科技有限公司) (“**Hangzhou Shukang**”), pursuant to which, the Company may, from time to time, purchase the Relevant Products from Hangzhou Shukang based on its business needs, and Hangzhou Shukang may, from time to time, supply the Relevant Products to the Company based on its business needs for a period from 21 August 2026 to 31 December 2026 (both days inclusive).

LISTING RULES IMPLICATIONS

Hangzhou Shukang is the wholly-owned subsidiary of Shukang Biopharmaceutical (Hangzhou) Co., Ltd. (數康生物醫藥(杭州)有限公司), a company owned as to approximately 95.65% by Dr. Zheng Pan (鄭攀), our executive Director. Therefore, Hangzhou Shukang is an associate of Dr. Zheng Pan, and thus a connected person of the Company under Chapter 14A of the Listing Rules. Accordingly, the transactions contemplated under the Raw Material Purchase Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios of the proposed annual cap of the transactions contemplated under the Raw Material Purchase Framework Agreement exceed 0.1% but less than 5%, the transactions contemplated thereunder are subject to reporting, announcement and annual review requirements but exempt from the independent shareholders' approval requirements under the Listing Rules.

THE RAW MATERIAL PURCHASE FRAMEWORK AGREEMENT

On 21 August 2026 (after the trading hours), the Company entered into the Raw Material Purchase Framework Agreement with Hangzhou Shukang, pursuant to which, the Company may, from time to time, purchase the Relevant Products from Hangzhou Shukang based on its business needs, and Hangzhou Shukang may, from time to time, supply the Relevant Products to the Company based on its business needs for a period from 21 August 2026 to 31 December 2026 (both days inclusive).

The principal terms of the Raw Material Purchase Framework Agreement are set out as below:

Date: 21 August 2026

Parties: (1) the Company; and
(2) Hangzhou Shukang

Term: From 21 August 2026 to 31 December 2026 (both days inclusive)

Major terms and conditions:

- (1) The Company may, from time to time, purchase the Relevant Products from Hangzhou Shukang based on its business needs, and Hangzhou Shukang may, from time to time, supply the Relevant Products to the Company based on its business needs for the Group's production purposes;
- (2) The delivery of the Relevant Products will be made to the Company's designated premises in Hangzhou by courier, logistics services or dedicated vehicles, at the delivery time agreed in the relevant purchase order; and
- (3) The products supplied by Hangzhou Shukang must comply with applicable national quality standards and/or the Company's requirements. Hangzhou Shukang is required to provide relevant qualifications, product certificates, testing reports and other supporting documents. The Company is entitled to inspect and test the products supplied by Hangzhou Shukang and reject products that fail to meet the agreed quality requirements.

**Consideration and
Pricing Policies :**

The price payable by the Company for purchasing the Relevant Products will be determined through arm's length negotiation between the parties, primarily with reference to the prevailing market price of the Relevant Products of same quality and the fees charged for historical transactions of similar nature. In the event of material changes in the expected annual purchase volume, significant fluctuations in the prices of the relevant products, or other material changes in market conditions, the agreed prices may be adjusted upon mutual negotiation and consent between both parties.

Payment Arrangement: The payment under the Raw Material Purchase Framework Agreement shall be paid by the Company by cash on the monthly basis upon receipt of the relevant invoices.

Implementation Agreements

The Company and Hangzhou Shukang will enter into, from time to time and as necessary, separate implementation agreements for each of the specific transactions contemplated under the Raw Material Purchase Framework Agreement during the term thereof. The detail of the supplied products, specifications, quantity, price and other relevant provisions will be set out in each implementation agreement. Any such implementation agreements will be within the ambit of the Raw Material Purchase Framework Agreement and the relevant annual cap, and if exceeded, the Company will comply with the relevant Listing Rules accordingly.

Proposed Annual Cap

The proposed annual cap (exclusive of value-added tax in the PRC) under the Raw Material Purchase Framework Agreement for the period from 21 August 2026 to 31 December 2026 is set out below:

**For the period
from 21 August
2026 to
31 December
2026
(RMB' million)**

Proposed annual cap (exclusive of value-added tax in the PRC)

7.5^(Note)

Note:

From 1 January 2026 and up to 20 August 2026, the Company had conducted the purchase of the Relevant Products from Hangzhou Shukang for a total of approximately RMB2.2 million (exclusive of value-added tax in the PRC). As all the applicable percentage ratios in respect of such transactions from 1 January 2026 to 20 August 2026 are less than 5%, and the total consideration is less than HK\$3 million, the relevant purchases are fully exempt under Rule 14A.76 of the Listing Rules.

The proposed annual cap for the period from 21 August 2026 to 31 December 2026 set out above is determined based on the following factors which are applicable to the Raw Material Purchase Framework Agreement:

- (a) the estimated orders for the Relevant Products for the period from 21 August 2026 to 31 December 2026;
- (b) the expected price of the Relevant Products for the period from 21 August 2026 to 31 December 2026; and
- (c) a buffer for any unexpected increase of procurement demands and the current market condition. The buffer projection is assumed solely for determining the annual cap and shall not be regarded as any indication directly or indirectly as to the trading prospects of the Company and Hangzhou Shukang.

REASONS FOR ENTERING INTO THE RAW MATERIAL PURCHASE FRAMEWORK AGREEMENT

The continuous glucose monitoring system (CGM) of the Company in the first half of 2026 achieved the revenue of RMB313.02 million, representing an increase of 118.7% as compared to the same period in 2025, indicating that the business remains in a phase of sustained and rapid growth. With the continued expansion of the CGM business, the Company expected that the demand of raw materials will further increase. To ensure the stable supply of raw materials for CGM products and fully leverage the advantages of economies of scale in purchase, the Company conducted a competitive selection process among market suppliers through price inquiries and comparisons. After comprehensively considering factors such as pricing levels, delivery capabilities, service guarantee and logistic costs, the Company selected Hangzhou Shukang for entering into the Raw Material Purchase Framework Agreement.

The Directors (including the independent non-executive Directors) are of the view that the terms of the Raw Material Purchase Framework Agreement (i) have been negotiated on an arm's length basis; (ii) have been conducted and will be conducted on normal commercial terms; (iii) are entered into in the ordinary and usual course of business of the Group; and (iv) are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

INTERNAL CONTROL MEASURES

In order to ensure that the transactions contemplated under the Raw Material Purchase Framework Agreement are conducted in accordance with the terms of the agreement, on normal commercial terms and in accordance with the pricing policies and principles set out therein, the Company will comply with its existing internal control measures, which include the following:

- (1) transaction will be conducted pursuant to an individual agreement which complies with the terms of the Raw Material Purchase Framework Agreement and the pricing policies and principles set out therein.
- (2) When assessing the pricing of a transaction, information with respect to referential purchase prices, such as those solicited from third-party suppliers and research from industry websites, among other things, will be made available to the relevant departments and personnel for their review and approval;
- (3) the internal audit department of the Company and the departments responsible for the connected transactions of the Company will monitor the transactions under the Raw Material Purchase Framework Agreement, and seek further information from individual departments where necessary to ensure, among other things, that such transactions are conducted in accordance with the terms of the Raw Material Purchase Framework Agreement and the pricing policies and principles set out therein. Such internal audit department will be monitored by the audit committee of the Board; and
- (4) the finance department will closely monitor the actual transaction amounts under the Raw Material Purchase Framework Agreement and closely and continuously review such amounts against the applicable annual cap. When the total transaction amounts under the Raw Material Purchase Framework Agreement exceed 80% of the relevant annual cap, the finance team will determine there is a possibility that the relevant annual cap may be exceeded and timely report to the management of the Company, which may consider actions to ensure compliance with the Listing Rules.

Pursuant to the Listing Rules, the independent non-executive Directors and the auditor of the Company will conduct an annual review of the continuing connected transaction under the Raw Material Purchase Framework Agreement in respect of whether, among other things, the transaction was conducted in accordance with the terms of the Raw Material Purchase Framework Agreement and whether the relevant proposed annual cap has been exceeded.

The Company will continue to adopt and implement such internal procedures and corporate governance measures for all ongoing and proposed continuing connected transactions of the Company in order to ensure that the pricing mechanism and terms of the transactions, are fair and reasonable and no less favourable than the terms provided by any independent third parties, so as to ensure that they serve the interests of the Company and its Shareholders as a whole.

By implementing such internal control measures and procedures, the Directors (including the independent non-executive Directors) consider that the Company has sufficient internal control measures and procedures to ensure that the transactions contemplated under the Raw Material Purchase Framework Agreement will be on normal commercial terms and no less favorable to the Company than that available from independent third parties.

INFORMATION OF THE PARTIES

The Company

The Company was incorporated in the PRC with limited liability, and has been dedicated to the research and development, and production and sales of medical devices for the monitoring, treatment and management of diabetes. The Company is ultimately controlled by Dr. Zheng Pan.

Hangzhou Shukang

Hangzhou Shukang is primarily engaged in production and sales of raw materials for medical devices. As at the date of this announcement, Hangzhou Shukang is ultimately owned as to approximately 95.65% by Dr. Zheng Pan. Therefore, Dr. Zheng Pan is the ultimate beneficial owner of Hangzhou Shukang as at the date of this announcement.

LISTING RULES IMPLICATIONS

As at the date of this announcement, Hangzhou Shukang is the wholly-owned subsidiary of Shukang Biopharmaceutical (Hangzhou) Co., Ltd., a company owned as to approximately 95.65% by Dr. Zheng Pan, our executive Director. Therefore, Hangzhou Shukang is an associate of Dr. Zheng Pan, and thus a connected person of the Company under Chapter 14A of the Listing Rules. Accordingly, the transactions contemplated under the Raw Material Purchase Framework Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios of the proposed annual cap of the transactions contemplated under the Raw Material Purchase Framework Agreement exceed 0.1% but less than 5%, the transactions contemplated thereunder are subject to reporting, announcement and annual review requirements but exempt from the independent shareholders' approval requirements under the Listing Rules.

Save for disclosed above, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiry, there is no other continuing transaction entered into between any member of the Group and Hangzhou Shukang and its ultimate beneficial owner or otherwise related, which would be, together with the transactions contemplated under the Raw Material Purchase Framework Agreement, aggregated under the Listing Rules.

Dr. Zheng Pan (who is the ultimate beneficial owner of Hangzhou Shukang), an executive Director, is considered to have material interests in the transactions contemplated under the Raw Material Purchase Framework Agreement by virtue of his equity interests in Hangzhou Shukang. For good corporate governance, Dr. Zheng Pan has abstained from voting on the relevant Board resolutions in the Board meeting to approve the transactions contemplated under the Raw Material Purchase Framework Agreement.

Save as disclosed, there is no other Director who has a material interest in the transactions contemplated under the Raw Material Purchase Framework Agreement.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms have the meanings set out below:

“associate”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors
“Company”	MicroTech Medical (Hangzhou) Co., Ltd.* (微泰醫療器械(杭州)股份有限公司), a limited liability company incorporated in the PRC on January 20, 2011 and converted into a joint stock limited liability company incorporated in the PRC on November 6, 2020, whose stock code is: HK2235
“connected persons”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries

“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“PRC”	the People’s Republic of China and for the purpose of this announcement, excluding Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan
“Relevant Products”	the raw materials for medical devices for diabetes monitoring, treatment and management
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholders”	the shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cents

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, 21 August 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.